Characterising CD8+ T cell transcriptomic and clonal consequences of immune checkpoint blockade for the treatment of cancer

Characterising CD8+ T cell transcriptomic and clonal consequences of immune checkpoint blockade for the treatment of cancer

<p><b>Background:</b> Immune checkpoint blockade (ICB) is arguably the greatest advance in medical oncology this century. Nonetheless, responses are highly variable. Mechanistic insights into this heterogeneity promises to improve patient stratification and identification of thera...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteur:	Watson, RA
Andere auteurs:	Fairfax, B
Formaat:	Thesis
Taal:	English
Gepubliceerd in:	2023
Onderwerpen:	Immunology Immuno-oncology Oncology, Experimental

Gelijkaardige items

Immune Checkpoint Blockade sensitivity and Progression-Free Survival associates with baseline CD8+ T cell clone size and cytotoxicity
door: Watson, R, et al.
Gepubliceerd in: (2021)

Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade
door: Sharmila Nair, et al.
Gepubliceerd in: (2021-01-01)

Dissecting peripheral CD8+ T cell responses and immune interactions during immune checkpoint blockade for metastatic melanoma
door: Tong, O
Gepubliceerd in: (2023)

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
door: Cristina Valero, et al.
Gepubliceerd in: (2023-10-01)

Mathematical modelling and transcriptional characterisation of intratumoral regulatory T cell sub-populations
door: Muzhingi, I
Gepubliceerd in: (2023)

Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
door: Robert W. Wilkinson, et al.
Gepubliceerd in: (2018-06-01)

New approaches to treating cancer using immune-checkpoint blockade
door: Fellermeyer, M
Gepubliceerd in: (2023)

FcγRIIB is a T cell checkpoint in antitumor immunity
door: Clara R. Farley, et al.
Gepubliceerd in: (2021-02-01)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
door: Jun Gong, et al.
Gepubliceerd in: (2018-10-01)

Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin)
door: Vassilis Genoud, et al.
Gepubliceerd in: (2021-11-01)

Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression
door: Joseph S. Dolina, et al.
Gepubliceerd in: (2023-09-01)

Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
door: Xiaoxin Ren, et al.
Gepubliceerd in: (2022-11-01)

A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity
door: Nadine Nelson, et al.
Gepubliceerd in: (2019-08-01)

IL-1 receptor–associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy
door: Gürcan Tunalı, et al.
Gepubliceerd in: (2023-04-01)

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas
door: Virginia Laspidea, et al.
Gepubliceerd in: (2022-04-01)

EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice
door: Armin Rehm, et al.
Gepubliceerd in: (2022-06-01)

Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells
door: Xinyi Jiang, et al.
Gepubliceerd in: (2023-05-01)

CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity
door: Madhura Modak, et al.
Gepubliceerd in: (2022-06-01)

Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer
door: Kentaro Masuhiro, et al.
Gepubliceerd in: (2022-05-01)

Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer
door: Colt A. Egelston, et al.
Gepubliceerd in: (2022-02-01)

CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy
door: Miriam Y. Kim, et al.
Gepubliceerd in: (2021-08-01)

Decitabine priming increases anti–PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models
door: Xiang Li, et al.
Gepubliceerd in: (2023-04-01)

Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell– and CXCR3-dependent manner
door: Michael Brandon Ware, et al.
Gepubliceerd in: (2023-04-01)

Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases
door: Jessica Tsukamoto, et al.
Gepubliceerd in: (2018-10-01)

Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer
door: Elizabeth Comen, et al.
Gepubliceerd in: (2024-02-01)

Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis
door: Tiina E. Kähkönen, et al.
Gepubliceerd in: (2021-06-01)

Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses
door: Gabrielle Romain, et al.
Gepubliceerd in: (2022-09-01)

Editorial: Tumor microenvironment complexity and its therapeutic implications
door: Denner Santos dos Anjos, et al.
Gepubliceerd in: (2025-01-01)

CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation
door: Kathryn E. Beckermann, et al.
Gepubliceerd in: (2020-08-01)

Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach
door: Gillian Murtagh, et al.
Gepubliceerd in: (2024-02-01)

PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors
door: Rebekka Duhen, et al.
Gepubliceerd in: (2022-06-01)

Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients
door: Max M. Wattenberg, et al.
Gepubliceerd in: (2021-03-01)

Immune regulatory networks in inflammation-driven cancer
door: Franchini, F
Gepubliceerd in: (2017)

Immune determinants of Barrett’s progression to esophageal adenocarcinoma
door: Kiran H. Lagisetty, et al.
Gepubliceerd in: (2021-01-01)

Tumor cells fail to present MHC-II–restricted epitopes derived from oncogenes to CD4+ T cells
door: Spencer E. Brightman, et al.
Gepubliceerd in: (2023-01-01)

CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer
door: Masayo Ukita, et al.
Gepubliceerd in: (2022-06-01)

A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation
door: Alessandro Mega, et al.
Gepubliceerd in: (2023-12-01)

IL-32γ potentiates tumor immunity in melanoma
door: Thomas Gruber, et al.
Gepubliceerd in: (2020-09-01)

Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
door: Eric Tu, et al.
Gepubliceerd in: (2022-02-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
door: Diana I. Albu, et al.
Gepubliceerd in: (2024-12-01)